Shots:

• Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months
• BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones on the selection of additional targets
• In 2016- the companies collaborated to develop & commercialize Ab targeting tumor-associated myeloid cells discovered using BioInvent's F.I.R.S.T drug discovery platform. The platform allows the discovery of human Ab utilizing n-CoDeR Ab library to identify targets

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: BioInvent